ONCSQ (OncoSec Medical) Effective Interest Rate on Debt %: 3.16% (As of Jan. 2023)


What is OncoSec Medical Effective Interest Rate on Debt %?

OncoSec Medical ONCSQ -99.00% Effective Interest Rate on Debt % is 3.16% as of Jan. 2023.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. OncoSec Medical's annualized positive value of Interest Expense for the quarter that ended in Jan. 2023 was $0.14 Mil. OncoSec Medical's average total debt for the quarter that ended in Jan. 2023 was $4.31 Mil. Therefore, OncoSec Medical's annualized Effective Interest Rate on Debt % for the quarter that ended in Jan. 2023 was 3.16%.

OncoSec Medical  (OTCPK:ONCSQ) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

OncoSec Medical Effective Interest Rate on Debt % Related Terms

OncoSec Medical Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical Effective Interest Rate on Debt % Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.76 0.13 0.21 0.31

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.20 0.34 0.78 3.16

ONCSQ vs NOVNQ, USRM, VRTX: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, OncoSec Medical's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSec Medical Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Effective Interest Rate on Debt % falls into.


OncoSec Medical Effective Interest Rate on Debt % Calculation

OncoSec Medical's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Jul. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Jul. 2021 )+Total Debt  (A: Jul. 2022 ))/ count )
=-1  *  -0.021/( (7.318+6.175)/ 2 )
=-1  *  -0.021/6.7465
=0.31 %

where

Total Debt  (A: Jul. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=5.238 + 2.08
=7.318

Total Debt  (A: Jul. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.127 + 2.048
=6.175

OncoSec Medical's annualized Effective Interest Rate on Debt % for the quarter that ended in Jan. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Oct. 2022 )+Total Debt  (Q: Jan. 2023 ))/ count )
=-1  *  -0.136/( (5.152+3.465)/ 2 )
=-1  *  -0.136/4.3085
=3.16 %

where

Total Debt  (Q: Oct. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.514 + 1.638
=5.152

Total Debt  (Q: Jan. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.127 + 1.338
=3.465

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jan. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 3.16% mean?
OncoSec Medical (ONCSQ) has a Effective Interest Rate on Debt % of 3.16% as of Jan. 2023. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on OncoSec Medical and its competitors.
Is OncoSec Medical's Effective Interest Rate on Debt % too high?
OncoSec Medical's current Effective Interest Rate on Debt % is 3.16%.
How does OncoSec Medical's Effective Interest Rate on Debt % compare to NOVNQ and USRM?
OncoSec Medical's Effective Interest Rate on Debt % of 3.16% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on OncoSec Medical and its competitors. OncoSec Medical's current Effective Interest Rate on Debt % is 3.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current Effective Interest Rate on Debt % of 3.16%. The current Effective Interest Rate on Debt % is 3.16%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current Effective Interest Rate on Debt % is 3.16% as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.